Iman Karimzadeh

Dr. Iman Karimzadeh

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2019 in Foods
Verified
Journal Article
Open access
PDF file
DDDorna Davani-Davari
Dorna Davani-Davari
MNManica Negahdaripour
Manica Negahdaripour
IKIman Karimzadeh
Iman Karimzadeh
Mostafa SeifanMostafa Seifan
Mostafa Seifan
MMMilad Mohkam
Milad Mohkam
YGYounes Ghasemi
Younes Ghasemi
Prebiotics are a group of nutrients that are degraded by gut microbiota. Their relationship with human overall health has been an area of increasing interest in recent years. They can feed the intestinal microbiota, and their degradation products are short-chain fatty acids that are released into blood circulation, consequently, affecting not only the gastrointestinal tracts but also other distant organs. Fructo-oligosaccharides and galacto-oligosaccharides are the two important groups of prebiotics with beneficial effects on human health. Since low quantities of fructo-oligosaccharides and galacto-oligosaccharides naturally exist in foods, scientists are attempting to produce prebiotics on an industrial scale. Considering the health benefits of prebiotics and their safety, as well as their production and storage advantages compared to probiotics, they seem to be fascinating candidates for promoting human health condition as a replacement or in association with probiotics. This review discusses different aspects of prebiotics, including their crucial role in human well-being.

27 August 2020 in Future Microbiology
Verified
Journal Article
Open access
EKElaheh Kordzadeh-Kermani
Elaheh Kordzadeh-Kermani
HKHossein Khalili
Hossein Khalili
IKIman Karimzadeh
Iman Karimzadeh
Aim: Despite the similarities in the pathogenesis of the beta coronaviruses, the precise infective mechanisms of SARS-CoV-2 remain unclear. Objective: In this review, we aim to focus on the propose...

15 January 2020 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
MMMotahareh Mahi-Birjand
Motahareh Mahi-Birjand
SYSajad Yaghoubi
Sajad Yaghoubi
MAMeghdad Abdollahpour-Alitappeh
Meghdad Abdollahpour-Alitappeh
ZKZahra Keshtkaran
Zahra Keshtkaran
NBNader Bagheri
Nader Bagheri
IKIman Karimzadeh
Iman Karimzadeh
Introduction: Aminoglycosides have long been used in antibacterial treatment and are still commonly used in clinical practice. Despite their extensive application and positive effects, drug-related toxicity is considered as the main obstacle of aminoglycosides. Aminoglycosides induce nephrotoxicity through the endocytosis and accumulation of the antibiotics in the epithelial cells of proximal tubule. Most importantly, however, a number of pharmacological agents were demonstrated to have protective activities against nephrotoxicity in experimental animals. Areas covered: In the present systemic review, the authors provide and discuss the mechanisms and epidemiological features of aminoglycoside-induced nephrotoxicity, and focus mainly on recent discoveries and key features of pharmacological interventions. In total, 39 articles were included in this review. Expert opinion: The majority of studies investigated gentamicin-induced nephrotoxicity in animal models. Antioxidants, chemicals, synthetic drugs, hormones, vitamins, and minerals showed potential values to prevent gentamicin-induced nephrotoxicity. Indicators used to evaluate the effectiveness of nephroprotection included antioxidative indexes, inflammatory responses, and apoptotic markers. Among the nephroprotective agents studied, herbs and natural antioxidant agents showed excellent potential to provide a protective strategy against gentamicin-induced nephrotoxicity.

31 May 2019 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
DDDorna Davani-Davari
Dorna Davani-Davari
IKIman Karimzadeh
Iman Karimzadeh
HKHossein Khalili
Hossein Khalili
Anabolic-androgenic steroids and growth hormone are among the most commonly used supplements by sportsmen and sportswomen. The aim of this systematic review is to collect and report available data about renal safety of anabolic-androgenic steroids and growth hormone (GH). The search strategy was in accordance with the PRISMA guideline. Seven databases such as Scopus, Medline, Embase, and ISI Web of Knowledge were searched using keywords, such as “growth hormone”, “anabolic-androgenic steroids”, and “kidney injury”. Articles published from 1950 to December 2017 were considered. Randomized clinical trials, prospective or retrospective human studies, case series as well as case reports, and experimental (in vivo) studies were included. Twenty one clinical and experimental articles were selected (12 for anabolic-androgenic steroids and 9 for GH). Anabolic-androgenic steroids can affect the kidney in different aspects. They can induce or aggravate acute kidney injury, chronic kidney disease, and glomerular toxicity. These adverse effects are mediated through pathways such as stimulating renin-angiotensin-aldosterone system, enhancing the production of endothelin, producing reactive oxygen species, over-expression of pro-fibrotic and pro-apoptotic mediators (e.g., TGF-β1), as well as inflammatory cytokines (e.g., TNF-α, IL-1b, and IL-6). Although GH may affect the kidney in different aspects, such as size, glomerular filtration rate, and tubule functions, either directly or indirectly, there is no conclusive clinical evidence about its detrimental effects on the kidney in athletes and body builders. Evidence regarding effects of anabolic-androgenic steroids exists; However, GH’s exact effect on the kidney at doses used by athletes and body builders has not yet been clarified. Cohort clinical studies with long-term follow-up are warranted in this regard.

1 June 2020 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
PGParisa Ghasemiyeh
Parisa Ghasemiyeh
ABAfshin Borhani-Haghighi
Afshin Borhani-Haghighi
IKIman Karimzadeh
Iman Karimzadeh
SMSoliman Mohammadi-Samani
Soliman Mohammadi-Samani
AVAfsaneh Vazin
Afsaneh Vazin
AQAdnan I Qureshi
Adnan I Qureshi
Stroke has been considered as one of the underlying diseases that increases the probability of severe infection and mortality. Meanwhile, there are ongoing reports of stroke subsequent to COVID-19 infection. In this narrative paper, we reviewed major neurologic adverse drug reactions (ADRs) and pharmacokinetics of drugs which are routinely used for COVID-19 infection and their potential drug–drug interactions (PDDIs) with common drugs used for the treatment of stroke. It is highly recommended to monitor patients on chloroquine (CQ), hydroxychloroquine (HCQ), antiviral drugs, and/or corticosteroids about initiation or progression of cardiac arrhythmias, delirium, seizure, myopathy, and/or neuropathy. In addition, PDDIs of anti-COVID-19 drugs with tissue plasminogen activator (tPA), anticoagulants, antiaggregants, statins, antihypertensive agents, and iodine-contrast agents should be considered. The most dangerous PDDIs were interaction of lopinavir/ritonavir or atazanavir with clopidogrel, prasugrel, and new oral anticoagulants (NOACs).

27 June 2020 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
AAAli Asadi-Pooya
Ali Asadi-Pooya
AAArmin Attar
Armin Attar
MMMohsen Moghadami
Mohsen Moghadami
IKIman Karimzadeh
Iman Karimzadeh